News > Zydus Cadila Completes Phase-2 Clinical Trial in Covid-19 Patients

Zydus Cadila Completes Phase-2 Clinical Trial in Covid-19 Patients

Drug firm Zydus Cadila on Thursday said it has successfully completed a phase 2 clinical trial in COVID-19 patients with its biological therapy, ‘PegiHep’, and it will now begin phase 3 clinical trial.

Zydus Cadila, which is a part of the Cadila Healthcare group, said Pegylated Interferon alpha 2b significantly increased viral reduction and reduced the need for supplemental oxygen in moderate COVID-19 patients.